Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Topline data is expected in Q3 of 2022. In other words, as early as sometime in July. After that the approval process may be beneficially affected by the fact of Orphan Drug Designation. As the April 12 press release stated...
"Iomab-B has been granted Orphan Drug Designation from the U.S. FDA and the European Medicines Agency (EMA). Iomab-B also has patent terms extending to at least 2036/2037 in the US and EU. In addition, Actinium received positive Scientific Advice from the Committee for Medicinal Products for Human Use (CHMP) of the EMA indicating that the Phase 3 SIERRA trial design, primary endpoint and planned statistical analysis are acceptable as the basis for a Marketing Authorization Application."
As the current partnership is for Europe and the Middle East the EMA approval may be the most important as future milestones and royalties will first flow from that partnership. Investors should anticipate some nice gains going into next year.
Very impressive April 2022 Corporate Presentation.
https://d1io3yog0oux5.cloudfront.net/_b6b779799f85b1b5c2814149a6dc8032/actiniumpharma/db/206/944/pdf/Actinium_Investor+Presentation_April+12+2022.pdf
This should be $30+ right now...even in this horrible market!
1. 22 million shares.
2. $100 million cash, $452 million milestones, 25% royalties for Europe and ME for first drug.
3. US and ROW to follow.
4. Large portfolio.
5. Collaboration with Astellas
6. BO in the $billions.(Astellas or Roche?)
Those who think that the Covid ship has sailed and Sorrento is too late are sadly mistaken IMO. New variants arise several times a year. And most of the world is inadequately vaccinated.
COVIMARK, COVISHIELD and Mpro have huge potential.
And cancer is not going away. ADNAB and DAR-T could each have a dozen targets...and could be partnered. As could SOFUSA.
And it is nice to have the CELU investment at $200+ million and on an upward trend.
And ABIVERTINIB and Socazolimab are very partnerable.
It is good to have 6 phase 3 and 6 phase 2 drugs in the portfolio.
Big Pharmas have massive cash reserves and depleted portfolios. Small portfolio rich biotechs like Sorrento will have their day!
Siphen posted an interesting history of Sorrento acquisitions...
https://www.reddit.com/r/srne/comments/u7k6tp/srne_accomplishments_2009now/?utm_source=share&utm_medium=web2x&context=3
Sorrento's investment in Celularity is worth $240 million this morning. Moving up nicely as July sales date approaches.
There is one big new emphasis on the Sorrento APRIL slide presentation. VIREX is mentioned on about 4 slides. Including slide 19. Clearly they are moving ahead rapidly on this program.
https://investors.sorrentotherapeutics.com/static-files/ded13448-aa64-4405-a2d9-de644cfe9dfc
Near PCR quality tests in 5 minutes at 10% of the cost of other tests looks like a winner to me!
This small cell lung cancer trial is one of half a dozen trials Sorrento partnered with Lee's Pharma.
Lee’s Pharm is a public biopharma company with over 20 years of operation in China and currently markets 14 products in the PRC.
Sorrento has licensed exclusive rights to Lee’s Pharm to develop and commercialize the fully human anti-PD-L1 mAb STI-A1014 for the greater Chinese market.
Sorrento has an other PD-L1 drug partnered with a Korean partner. It is in trials in Korea and the US.
Sorrento has this excellent anti-PD-L1 drug in pivotal phase 3 in China.
Efficacy and safety of the anti-PD-L1 monoclonal antibody
Socazolimab in combination with carboplatin and etoposide
for extensive-stage small cell lung cancer: Results from the
phase Ib clinical trial
Background: The study (ClinicalTrials.gov, NCT04346914) is an open, single-arm phase 1b clinical trial investigating the safety, tolerability, and efficacy of the recombinant human anti-programmed death-ligand 1 (PD-L1) monoclonal antibody Socazolimab in combination with carboplatin and etoposide in the first-line treatment of extensive-stage small cell lung cancer. Excellent safety and efficacy had been demonstrated in
previous phase I clinical trials.
Methods: Patients received Socazolimab (5mg/kg) every three weeks until disease
progression or physician decision. Carboplatin injections were administered every
three weeks under the same dosing schedule, and continuous etoposide injections (100mg/m2 ) on days 1, 2, and 3 of the 3-week treatment cycle. The primary endpoint of the study was safety. Secondary endpoints included the objective response rate
(ORR), progression-free survival (PFS), disease control rate (DCR), duration of
response (DOR), and overall survival (OS).
Results: From 15th April 2020 (enrollment date) to 30th December 2021 (data cutoff),
20 patients with extensive-stage small lung cell cancer were administered with
Socazolimab, carboplatin and etoposide. ORR was 70.0% (95% CI: 45.72%, 88.11%).
Median PFS was 5.65 months (95% CI: 4.14, 6.54), and the median DOR was 4.29
months (95% CI: 2.76, 5.85). Median OS was 14.88 months (95% CI: 10.09, NE). 95%
of patients experienced grade 3 and above treatment-related adverse events. No
treatment-related deaths had occurred.
Conclusions: Results revealed that the combination therapy of Socazolimab, carboplatin and etoposide demonstrated good safety and anti-tumor activity for the firstline treatment of extensive-stage small cell lung cancer, with an OS higher than those
of previous clinical trials, notably IMPOWER133 (12.3 months) and CASPIAN (12.9
months). A phase III, randomized, placebo-controlled clinical trial (ClinicalTrials.gov,
NCT04878016) is currently being conducted with 498 patients.
Glad to see that the COVIMARK marketing plan in the US includes CVS, Walgreens, Walmart, Costco, Sam's club, Target and Amazon. You can't do breath tests at home!
http://covimark.com/obtain
Yes they keep mentioning CBD. See slide 6 of the March Corporate Presentation.
https://investors.sorrentotherapeutics.com/static-files/ded13448-aa64-4405-a2d9-de644cfe9dfc
They have other holdings but at this hour their CELU holding is worth $212 million.
Income over $100 million from Covistix in Q1 2022?
No way IMO!
How about $30-40 million range?
I would then expect it to ramp up each quarter. That is how sales campaigns go. In Q1 they did not even have manufacturing ramped up in order to fill big orders. In the US I would expect them to use the Scilex sales force. That could help get US sales moving nicely.
And if they can break into the CHINA market...WOW!
CELU shares held by Sorrento are now worth over $200 million. IMO they could be worth $300-$400 million by the middle of July. And meanwhile the ZTlido sales should reach $100 million this year!
And there is a lot of good news coming on SEMDEXA. I expect Priority Review. Multi-billion worldwide sales potential.
And Mpro oral anti-viral should enter the clinic any day now. Better and safer than Big Pharma versions!
And COVI-MARK approvals and sales should be coming in US, Canada and CHINA . Covid is not over. Variants will increase in Southern hemisphere winter followed by Northern hemisphere winter! COVISHIELD will be needed!
And a dozen cancer programs are in phase 2 and 3. All are partnerable at that stage!
Meanwhile 3 SOFUSA and 2 RTX programs are advancing with huge potential.
Good time to average down IMO.
Wink, wink. Nudge , nudge. I know that when you say sell, you buy! You want others to sell so you can buy! Very clever.
Interesting thoughts from profromdover!...
" I do believe a BO or white knight will appear once SEMDEXA is in the money. I prefer a white scenario myself, but if a BO is going to happen I believe a bidding war will break out for SRNE. MRNA stock is way down from it's high, ABBV needs another blockbuster once HUMIRA comes off patent in Jan, 2023. You can go down the list of the top 10 big pharma, and they all will want the 1st non-opioid pain med along with the rest of the SRNE's break thru devices & meds coming thru P3 trials sucessfully. The big pharmas need to accumulate new products to keep growing, the pressure is on them to acquire the best available, and we have some of the best available coming on line the next 2 years."
FUJOVEE and OQORY are the new names for Abivertinib and COVI-MSC. We should hear more about both of these plus SEMDEXA, Mpro oral antiviral, and COVI-MARK this month.
https://sorrentotherapeutics.com/research/pipeline/
It will be interesting to see if Sorrento's cancer portfolio will benefit from the latest FDA move. The FDA oncology chief aims to open up accelerated approval for earlier cancer treatment under 'Project FrontRunner'.
For decades, the FDA has been offering accelerated approvals to open early access to new cancer drugs, but mostly for patients who’ve already tried several other regimens. FDA oncology chief Richard Pazdur, M.D., now plans to disrupt that longstanding practice with a new initiative.
Called “Project Front-Runner,” the new program will come online later this year, Pazdur, director of the FDA’s Oncology Center of Excellence, told Fierce Biotech in an interview. Although details are still in the works, the program’s theme is clear—to advance accelerated approval to earlier cancer treatment.
https://www.fiercebiotech.com/biotech/fda-oncology-chief-eyes-accelerated-approval-earlier-cancer-treatment-under-planned-project
Cancer portfolio...Blockbusters
Abivertinib
PD-L1 (Socazolimab)*
PD-L1 (STI-3031)**
CD47
CD38 DAR-T
TROP2 ADC
SeprehvecTM oncolytic virus
BCMA ADC
Bevacizumab-ADNABTM
Rituximab-ADNABTM
Liquid Tumors
Endometrial Cancer
Ovarian Cancer
B-Cell Lymphoma
COVISHIELD Antibody: NEUTRALIZING ANTIBODY THERAPEUTICS...Blockbuster!
• STI-9167 developed at Sorrento in
collaboration with scientists at the
Mt. Sinai Center for Therapeutic
Antibody Development.
• STI-9167 displays potent in vivo
neutralization of SARS-CoV-2 and
Variants of Concern (VoC),
including Alpha, Beta, Gamma,
Delta, Omicron BA.1 and Omicron
BA.2
• Phase 1 clinical trials ongoing
for STI-9199 (COVISHIELD IN) in
healthy individuals and infected
patients, and planned for IV
formulation (STI-9167, COVISHIELD)
STI-9167 potently neutralizes all known
SARS-COV-2 VoCs
Virex Health: DIAGNOSTIC PIPELINE....Blockbuster!
• Virex Health, Inc. is a Boston, Massachusetts company that has developed a powerful,
broadly applicable at-home diagnostic platform (“Virex Technology”).
• Virex Technology, invented and developed by Boston University (BU) Professors Mark Grinstaff and Scott Schaus and Virex scientists, employs widely used electrochemistry found in household diabetes glucometer devices for next generation diagnostics.
• Virex Technology has demonstrated extremely high sensitivity for multiple biological analytes including COVID-19 virus detection as sensitive as 10 TCID50, rivalling PCR sensitivity.
• Virex’s early liver cancer biomarker test detects a liver cancer biomarker in as little as 5 microliters of blood.
• Virex’s diagnostic tests provide qualitative and/or quantitative results in as little as 5 minutes.
• Virex’s diagnostic tests leverage existing worldwide manufacturing infrastructure for glucometers and glucose strip tests to provide affordable and highly scalable next-generation diagnostic solutions for COVID-19 tests, early cancer detection and beyond.
I was glad to see a Sorrento critic point out that the current share price values the ENTIRE SORRENTO PORTFOLIO at NEGATIVE $1+ Billion after you subtract the $2 Billion value of CELU and the Silex SPAC!
In other words COVIMARK, Mpro, COVISHIELD, ABIVERTINIB, ADNAB, DAR-T, SOFUSA, VIREX, SMARTPHARM etc. are worth less than NOTHING!
It makes you wonder why BLACKROCK holds more than 22 million shares!
And makes me look again at the recent portfolio....the best small biotech value I have found!
https://investors.sorrentotherapeutics.com/static-files/ded13448-aa64-4405-a2d9-de644cfe9dfc
It will be interesting to see what COVISTIX revenue will be revealed from Q1 2022 report. I expect it to ramp up quarter over quarter for the rest of the year. And I would expect US and Canadian approvals very soon. But what I am most interested in is the VIREX technology.
Near PCR quality, 5 minute tests at about 10% of the cost of other technologies would be a real winner. And it would have application to many viruses and many cancers. Just think if there are such tests available for lung, pancreatic, ovarian and brain cancers that are frequently discovered too late, whereas if they were detected early, could be cured! I know one of the consulting scientists worked for the Livermore Laboratory and BARDA. It is cutting edge technology!
With Ztlido sales possibly reaching $100 million this year and the Celularity investment worth about $200 million and new COVIMARK sales coming any day now ...I look forward to news about SEMDEXA, Mpro, COVISHIELD, ABIVERTINIB, ADNAB, DAR-T, SOFUSA, VIREX and several other programs advancing significantly this year!
SEMDEXA, RTX, COVIMARK, Mpro, COVISHIELD, ABIVERTINIB, ADNAB, DAR-T and SOFUSA are all examples of potential multi-blockbusters. Any Big Pharma would be interested IMO!
If I was the CEO of a Big Pharma with a lot of cash and a shrinking pipeline would I be interested in a partnership with Sorrento focused on ABIVERTINIB? Possibly.
But would I be more interested in a wider partnership which included the entire cancer portfolio, Covid portfolio and non-opioid pain portfolio? Probably!
And would I want to secure a Genentech/Roche model, partnership followed by buyout, if Sorrento is interested? Certainly!
And if Dr. Ji is not interested in such a deal do you think the large institutions who now own over 30% of the company and the large retail base of the company would support such a deal? I do!
Neither the Institutions nor the long term retail shareholders would support a low level stink bid. But if the bidding started at $50-$60 a share interest would be high IMO! I expect several Big Pharma might be interested!
I would consider doing both.
About SEMDEXA....I like PaulSnowman's summary...
" when you have a biotech with a drug that’s in Fast Track and applying for BreakThrough Designation and has besides sciatica many off label indications and is non opioid, well tolerated, and non black label, I’m sorry but I’m keeping my chips in the pot. It’s as simple as that. "
Sciatica is a huge indication but the off label indications are even larger!
The phase 2/3 study of oral ABIVERTINIB in treating ARDS in Covid patients is important. Apparently the phase 2b will be to identify the most effective dose level. If they can identify an even better dose level than was used in the previous two phase 2 trials that would be great! Nice to see it will take place in the US, Mexico and Brazil. They already have hospital connections in all three countries.
They have already identified that the sweet spot for the use of ABIVERTINIB is in patients requiring oxygen support by non-invasive ventilation or high flow oxygen. This portion of the patient population were shown to be up to 5-fold more likely to benefit than those requiring low flow supplementation.
Covid ARDS and non-Covid ARDS are a very large unmet medical need. An oral treatment would be very useful and affordable!
In a late March interview Dr.Ji emphasized SEMDEXA aiming for Breakthrough Designation followed by marketing approval within 6 months...target late 2022 or early 2023. Also Mpro oral antiviral enter clinic in April with signs it does not have drug/drug interactions of the Pfizer drug. COVISHIELD covers all covid variants and might be ready in Q4 2022. COVIMARK approval packages before US FDA and Health Canada. AND application for COVIMARK APPROVAL IN CHINA...gigantic market!
Here are 10 potential news items in 2022 and/34 top programs out of the 70+ total pipeline.
1. ABIVERTINIB $61 Billion global market partnership(s). There would be multi-billion upfront, milestone and royalty payments. They announced partnering intentions in June last year! Remember the Genentech/Roche scenario!
2. SCILEX SPINOFF. More SEMDEXA news is due any day. This new treatment could gross $6-10 billion annually in the US alone!.
3. COVISTIX(COVIMARK) REVENUE STREAM. Sales have recorded in Q1 of 2022. Mexico leads the way and Europe, Central and South America, Canada, Japan and the US will follow. 30 million monthly test production near term! And now seeking approval in huge China market!
4. COVIDROPS, COVI-MSC, COVISHIELD, SEMDEXA, ABIVERTINIB(cancer and Covid) news is expected in 2022 and more EUA's. SEMDEXA and ABIVERTINIB potential revenue in 2H of 2022?
5. COVIDROPS is in phase 2 in the US and UK. Soon to enter a pediatric trial in Mexico. An Interim analysis of the UK out-patient trial any day.
6. COVI-MSC is in phase 2 trials in the US and Brazil The Brazilian study is pivotal. In Brazil it is followed by a trial for long-haul Covid patients.
7. ORAL MP18 based PAN-COVID ANTI-VIRAL. A peer-reviewed publication was released showing strong pan-Covid activity (including Omicron). A prestigious European journal made it front page news. This could enter the clinic in Q2(April).
8. In Cancer Sorrento has more than 10 fully human antibodies in the clinic or late pre-clinical(PD-1, PD-L1, CD38, CD123, CD47,BCMA, TROP2, LAG3, CTLA-4 and CD137). An allogenic DAR-T, an anti-TROP2 ADC and a second generation oncolytic virus(Seprehvec) will enter the clinic with several ADNAB(Mayo Clinic) drugs.
9. Non-opioid RTX is in phase 2 for arthritic knee pain and will enter phase 2 for epidural delivery for severe cancer pain in Q1.
10. Sofusa will report on a phase 1 arthritis treatment in Q2. Also is being tested in delivering cancer therapies including a collaboration with the Mayo Clinic to test lymphatic delivery.
And have a look at the top 34 portfolio items from the SRNE website. No wonder Blackrock holds over 22 million shares!
https://sorrentotherapeutics.com/research/pipeline/
FUNDING? Sorrento has invested wisely and has millions of shares of Celularity and ImmuneOncia. These are worth many hundreds of millions and the PSS binding arbitration could be settled with very large potential gains. It has many attractive programs to partner for upfront, milestone and royalty payments!
If you have an extra 17.5 minutes you may want to listen to Dr.Ji being interviewed on Benzinga. The interviewer tries to press Dr.Ji on timelines...but I think Henry has learned not to over promise! Here are a few things that stood out to me.
It is clear that SEMDEXA could be approved late 2022 or early 2023.
And the powerful COVISHIELD nAB could be approved in Q4 2022.
And the oral antiviral Mpro will be in the clinic in April 2022.
And COVIMARK approvals are being sought in US, Canada and CHINA!
You can hear it from the 10:30 to 28:00 mark.
I think the bad vibe about Mexico must have been caused by that last tamale you ate. The fact that Sorrento announced that COVI-mRNA would be developed in Mexico first, tells me they have very good things happening there.
The big news about applying for approval and sales of COVISTIX in China is very big news. China uses Billions of tests a month and the Fortune factory production could all be utilized in China while new San Diego based production lines will be needed for North American sales!
SEMDEXA and oral anti-viral Mpro news and COVISHIELD news is very good indeed. Three blockbusters IMO!
In Benzinga interview Dr.Ji emphasized SEMDEXA aiming for Breakthrough Designation followed by marketing approval within 6 months. Also Mpro oral antiviral enter clinic in April with signs it does not have drug/drug interactions of the Pfizer drug. COVISHIELD covers all covid variants. COVIMARK approval packages before US FDA and Health Canada. AND application for COVIMARK APPROVAL IN CHINA...gigantic market!
Sorrento's Covid portfolio...tests, drops and vaccine could be needed.
‘This virus has fooled us before’: Here’s how Fauci predicts stealth Omicron will spread across the U.S.
The BA.2 subvariant of COVID, known as ‘stealth Omicron,’ is on the rise in Europe, Asia and, more recently, the U.S.—accounting for roughly 30% of all new infections this week, according to the U.S. Center for Disease Control and Prevention (CDC).
The spectre of a new COVID wave, caused by yet another mutation of the coronavirus is troubling. But, according to the White House’s top medical advisor, Dr. Anthony Fauci, the spread of stealth Omicron likely won’t be as disastrous as previous waves.
Is stealth Omicron more contagious?
On Sunday, Fauci told ABC’s This Week that the subvariant was between 50% and 60% more transmissible than original Omicron—which was already the most virulent form of COVID yet.
“The bottom line is we’ll likely see an uptick in cases, as we’ve seen in the European countries, particularly the U.K.,” Fauci said, adding that he doesn’t think an “uptick” will evolve into a full-blown “surge.”
The stealth Omicron subvariant has already become the dominant form of COVID worldwide, the World Health Organization (WHO) says, accounting for 86% of all COVID infections in the past month. But, in the U.S., stealth Omicron only accounts for roughly 30% of total new cases, which means the subvariant still has room for growth.''
The March 2022 presentation outlines Sorrento's Mpro oral anti-viral which is as effective against Omicron as Pfizer's drug but is projected to avoid drug/drug interactions.(slide 24). A better but safer Mpro would be a winner!
The March 2022 presentation outlines the 5 minute,near PCR sensitivity VIREX tests(slide 19)
DIAGNOSTIC PIPELINE
• Virex Health, Inc. is a Boston, Massachusetts company that has developed a powerful,
broadly applicable at-home diagnostic platform (“Virex Technology”).
• Virex Technology, invented and developed by Boston University (BU) Professors Mark
Grinstaff and Scott Schaus and Virex scientists, employs widely used electrochemistry
found in household diabetes glucometer devices for next generation diagnostics.
• Virex Technology has demonstrated extremely high sensitivity for multiple biological
analytes including COVID-19 virus detection as sensitive as 10 TCID50, rivalling PCR
sensitivity.
• Virex’s early liver cancer biomarker test detects a liver cancer biomarker in as little as
5 microliters of blood.
• Virex’s diagnostic tests provide qualitative and/or quantitative results in as little as 5
minutes.
• Virex’s diagnostic tests leverage existing worldwide manufacturing infrastructure for glucometers and glucose strip tests to provide affordable and highly scalable next-generation diagnostic solutions for COVID-19 tests, early cancer detection and beyond.
Don't underestimate the importance of Sorrento's PAIN portfolio.
100 Million Plus in Chronic Pain in U.S.
By Emily P. Walker, Washington Correspondent, MedPage Today
Published: June 30, 2011
WASHINGTON — Chronic pain affects 116 million Americans and costs the U.S. as much as $635 billion each year, according to a new report from the Institute of Medicine (IOM) that called for changes in how chronic pain is managed.
Much of the chronic pain experienced by Americans isn’t treated correctly, in part because doctors are not taught in medical school how to help patients manage pain, according to the report, entitled “Relieving Pain in America: A Blueprint for Transforming Prevention, Care, Education, and Research,” which was mandated by the healthcare reform law.
Chronic pain is so widespread and poorly understood that it’s a public health issue and a major “national challenge,” concluded the Committee on Advancing Pain Research, Care, and Education, which was made up of 18 experts in pain management, anesthesiology, bioethics, statistics, and immunology.
“Given the large number of people who experience pain and the enormous cost in terms of both dollars and the suffering experienced by individuals and their families, it is clear that pain is a major public health problem in America,” said committee chair Philip Pizzo, MD, professor of microbiology and immunology at Stanford University School of Medicine, in a press release.
Chronic pain is “more than a physical symptom” and can be influenced by genetics, stress, depression, and behavioral, cultural, and emotional factors, the committee wrote.
Moreover, long-term, persistent pain, which may have been caused by an injury or a disease, can cause changes in the nervous system, which in turn cause the pain to become its own distinct chronic disease.
The report called for a cultural change in order to prevent, assess, treat and understand all types of pain and laid out a blueprint for providing relief from pain.
It directs the Department of Health and Human Services to develop a plan to increase awareness about pain and its health consequences; improve how pain is assessed in the healthcare setting and how treatment of pain is paid for by the federal government; and to address disparities in how different groups of people experience pain..."
One great product producing revenue NOW.
*COVISTIX(COVIMARK): Marketing approval in Mexico, Brazil and Europe. Sales initially limited by low volume of production. Recently ramping up to 30 million a month range...and could exceed 50 million or more by year end.
Approval applications completed in Canada, US and World Health Organization. Affordable, 15 minute, highly accurate for all Covid variants. Could easily exceed $750 million in sales annually.
The next great product producing revenue by year end 2022.
*SEMDEXA:Great safety and efficacy results in pivotal Phase 3. Already has Fast Track, and will seek Breakthrough Designation and Priority Review before Mid-2022. These allow for approval within 6 months! Multi-Billion Sciatica market followed by many other indications estimated at an additional 50-200%.
These programs will finance the rest of the portfolio...COVISHIELD, Mpro, mRNA vaccine, ADNAB, DAR-T, RTX, SOFUSA etc. etc.
For many the Sorrento share price is down from their original purchase.
Many have taken the opportunity of the current biotech market slump to average down.
I have added shares recently so am doing well! And I expect the biotech market to heat up and look forward to increased COVISTIX sales and a large market for SEMDEXA. I also am very bullish on the ADNAB and DAR-T programs as well as RTX and SOFUSA!
Many excellent small biotechs are down at the moment...but none with better portfolios than Sorrento IMO!
Everyone should do their own dd and do what is best for them.
An Universal Covid vaccine is exactly what is needed.
And Sorrento has come up with a safer Universal chimeric mRNA version.
And Sorrento has wisely chosen to begin with Mexico and the vast Latin American markets to speed up EUA approvals.
Sorrento obviously has developed expertise with mRNA and this will mean it
can also extend this technology to Cancer and Inflammatory diseases.
Can you imagine cancer therapies with the 90-95% efficacy of the current mRNA Covid vaccines? Many cancer treatments today have about 10-15% efficacy!